JLE

Hépato-Gastro & Oncologie Digestive

MENU

(Neo)adjuvant chemotherapy of resected colorectal cancer liver metastases Volume 19, issue 2, Février 2012

Figures

See all figures

Authors
Hôpital Ambroise Paré, hépato-gastro-entérologie et oncologie digestive, Boulogne Billancourt, 9 avenue Charles de Gaulle, 92100 Boulogne-Billancourt, Université Versailles Saint-Quentin en Yvelines, Versailles, Hôpital Ambroise Paré, chirurgie digestive et oncologique, Boulogne Billancourt, Hôpital René Huguenin, oncologie médicale, Institut Curie, Saint-Cloud

Colorectal cancer (CRC) liver metastases (LM) are very common but only 20 to 30% of them will be resectable with, in this case, prolonged survival and a possibility to be cured. Their surgical resection should be systematically discussed in multidisciplinary meeting and be re-evaluated when a response to induction chemotherapy has been observed for LM that were not initially resectable. Recurrence, especially in the liver, are common. Perioperative chemotherapy with FOLFOX reduces the risk of recurrence of resectable LM but expose to the risk of missing metastases that can make their resection a problem.